NOE 115
Alternative Names: NOE-115Latest Information Update: 21 May 2024
Price :
$50 *
At a glance
- Originator Roche
- Developer Noema Pharma
- Class Behavioural disorder therapies
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Vasomotor symptoms
- Phase I Binge-eating disorder; Depressive disorders
Most Recent Events
- 22 Apr 2024 Phase-II clinical trials in Vasomotor symptoms in USA (PO) (NCT06385795)
- 12 Dec 2022 Phase-I clinical trials in Binge-eating disorder in Switzerland (Parenteral)(Noema Pharma pipeline, December 2022)
- 12 Dec 2022 Phase-I clinical trials in Depressive disorders in Switzerland (Parenteral)(Noema Pharma pipeline, December 2022)